Lexeo COO logs stock grant and tax sale

Lexeo Therapeutics, Inc. chief operating officer Jose Manuel Otero reported two equity transactions in company common stock.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. chief operating officer Jose Manuel Otero reported two equity transactions in company common stock. On June 29, he received 12,060 shares at no cost as a grant or award, increasing his direct holdings. On July 1, he sold 4,666 shares at a weighted average price of $4.48 per share to cover tax obligations related to the release of performance Restricted Stock Units, according to the footnotes. After these transactions, he directly holds 137,482 shares, which include 100,621 RSUs, indicating the sale represents a small portion of his overall position.

Insider Trade Summary

Net Seller: 4,666 shares

Net Sell 2 txns

Insider Otero Jose Manuel

Role Chief Operating Officer

Sold 4,666 shs ($21K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,666	$4.48	$21K
Grant/Award	Common Stock	12,060	$0.00	$0.00

Holdings After Transaction: Common Stock — 137,482 shares (Direct)

Footnotes (3)

1. F1. Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs").
2. F2. This transaction was executed in multiple trades at prices ranging from $4.35 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. Includes 100,621 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Key Figures

Shares sold: 4,666 shares Sale price: $4.48 per share Awarded shares: 12,060 shares +2 more

5 metrics

Shares sold 4,666 shares Sale on July 1, 2026 to cover RSU tax obligations

Sale price $4.48 per share Weighted average sale price for 4,666 shares

Awarded shares 12,060 shares Stock grant on June 29, 2026 at $0.00

Shares held after 137,482 shares Direct common stock holdings following transactions

RSUs included 100,621 RSUs RSUs included within total direct holdings after transactions

Key Terms

Restricted Stock Units, performance Restricted Stock Units, weighted average sale price

3 terms

Restricted Stock Units financial

"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance Restricted Stock Units financial

"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs")."

Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

FAQ

What insider transactions did Lexeo Therapeutics (LXEO) report for Jose Manuel Otero?

Lexeo’s chief operating officer reported one equity grant and one share sale. He received 12,060 shares as a stock award, then sold 4,666 shares mainly to cover tax obligations on performance RSU vesting.

How many Lexeo Therapeutics (LXEO) shares did the COO sell and at what price?

He sold 4,666 shares of Lexeo Therapeutics common stock at a weighted average price of $4.48 per share, with individual trades executed between $4.35 and $4.73, as disclosed in the filing footnotes.

Why did the Lexeo Therapeutics (LXEO) COO sell 4,666 shares?

The sale of 4,666 shares was made to cover tax obligations on the release of performance Restricted Stock Units. This type of transaction is tied to compensation-related vesting rather than a discretionary open-market reduction of his investment.

What new equity award did the Lexeo Therapeutics (LXEO) COO receive?

He received 12,060 shares of common stock as a grant or award at zero cost. This award increased his direct ownership and forms part of his overall equity-based compensation at Lexeo Therapeutics.

How many Lexeo Therapeutics (LXEO) shares does the COO hold after these transactions?

After the reported grant and sale, he directly holds 137,482 shares of common stock. This total includes 100,621 Restricted Stock Units, each representing a contingent right to receive one Lexeo common share in the future.

What are RSUs in the context of Lexeo Therapeutics (LXEO) insider holdings?

Restricted Stock Units, or RSUs, are promises to deliver shares in the future if conditions are met. The COO’s position includes 100,621 RSUs, each representing a contingent right to receive one share of Lexeo common stock upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 06:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		A		12,060	A	$0	142,148	D
Common Stock	07/01/2026		S(1)		4,666	D	$4.48(2)	137,482(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $4.35 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 100,621 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

	/s/ Youjin Choi, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)